Unknown

Dataset Information

0

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism.


ABSTRACT: We assessed the effects of antiandrogen therapy on ECG parameters of ventricular repolarization related to arrhythmic risk in 35 patients aged 70.3?±?7 years with advanced prostate cancer treated with degarelix associated with enzalutamide (group A, 26 patients) or degarelix monotherapy (group B, 9 patients). We analyzed Fridericia corrected Q-T interval (QTc), Q-T dispersion (QTd), J-Tpeak interval (JTp), mean and maximum Tpeak-Tend interval (Tpe) and Tpe/QT ratio, Tpeak-Tend dispersion (Tped), index of cardio-electrophysiological balance (iCEB) from ECG tracings, and occurrence of ventricular premature beats (VPB) recorded by Holter ECG, before initiation of medication (M0) and after 6 months of treatment (M1). The groups had similar demographics except for a higher prevalence of prior myocardial infarction in group B (p?=?0.01). All patients had low serum testosterone at M1. Baseline QTc, QTd, maxTpe/QT, meanTpe, maxTpe, Tped values were higher in B compared to A. They had a significant prolongation at M1 only in A. 20 patients in A and 6 in B had a 10% prolongation or decrease of iCEB (p?=?0.66). In 5 patients, VPB severity increased from non-complex to complex: 3 in A and 2 in B (p?=?0.31), but no sustained ventricular arrhythmia was registered. In conclusion, after 6 months of treatment, patients with hypogonadism on degarelix associated with enzalutamide had significant prolongation of QTc, QTd, maxTpe, meanTpe/QT, maxTpe/QT, Tped compared to patients on degarelix alone. The proportion of patients with 10% iCEB variation was similar between groups. There was no record of severe arrhythmias during the first 6 months of treatment.

SUBMITTER: Gheorghe ACD 

PROVIDER: S-EPMC7266846 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6220840 | BioStudies
2016-01-01 | S-EPMC5421403 | BioStudies
1000-01-01 | S-EPMC4698188 | BioStudies
2020-01-01 | S-EPMC7543547 | BioStudies
2015-01-01 | S-EPMC4386951 | BioStudies
2020-01-01 | S-EPMC7722753 | BioStudies
2016-01-01 | S-EPMC5201270 | BioStudies
2019-01-01 | S-EPMC6435291 | BioStudies
2016-01-01 | S-EPMC5201230 | BioStudies
2018-01-01 | S-EPMC6129769 | BioStudies